Thursday, May 3 & Friday, May 4, 2018

Posters will be displayed for the duration of the Conference during Exhibition Hours. Presenters are required to stand by their poster during BOTH Poster Mixer with Poster Discussion Sessions (Thursday, May 3 & Friday, May 4 - 17:30-18:30) to answer questions from Conference delegates. Please note that two poster presentations will be awarded the Best Poster Awards during the Presidential Closing Address on Saturday, May 5.

POSTER SETUP AND TAKE DOWN
Setup hours: Thursday, May 3, 2018, 08:00-11:00
Take down hours: Saturday, May 5, 2018, 14:00-17:00; any posters not removed by 17:00 will be discarded.

17:30 - 18:30    Poster Mixer with Poster Discussions
Room: Confederation II/III - Level 4

Track: Basic Science

PP01.01: Functional Implication of SETD2 Tumor Suppressor Gene in Mesothelial Carcinogenesis
Lisa Quetel, Inserm UMR-1162, France

PP01.02: Intra-Tumoral Molecular Heterogeneity in Malignant Pleural Mesothelioma
François Montagne, Inserm UMR-1162, France

PP01.03: Role of GITRL-GITR System in Promoting Proliferation of Malignant Mesothelioma
Mei-Lin Chan, Toronto General Hospital and Princess Margaret Cancer Centre, Canada

PP01.04: Malignant Pleural Mesothelioma Interactome with 367 Novel Protein-Protein Interactions
Madhavi Ganapathiraju, University of Pittsburgh, United States

PP01.05: Novel Insights on Disease Biology from Malignant Pleural Mesothelioma Interactome
Madhavi Ganapathiraju, University of Pittsburgh, United States

PP01.06: Mesothelioma Cells Exhibit Addiction to the Anti-Apoptotic Protein Bcl-xL and Are Sensitized to Radiation by BH3-Mimetics
Miranda Ashton, University of Glasgow, United Kingdom

PP01.07: Ubiquitin-Dependent Regulation of DNA Damage Tolerance in Mesothelioma
Ludovic Dhont, University of Liège, Belgium
PP01.08: “Asbestos-Free” Mesothelioma: Evaluating the Carcinogenicity of Cleavage Fragments following Hill’s Criteria
Joan Steffen, Never Again Consulting, United States

PP01.09: Calretinin Promotes Invasiveness and EMT in Mesothelioma Cells Involving the Activation of the FAK Signaling Pathway
Janine Wörthmüller, University of Fribourg, Switzerland

PP01.10: Evaluation of Antibody Drug Conjugates Targeting 5T4 in Mesothelioma
Laurel Schunselaar, The Netherlands Cancer Institute, Netherlands

PP01.11: Aclarubicin as a Promising Novel Therapeutic Option in Mesothelioma
Laurel Schunselaar, The Netherlands Cancer Institute, Netherlands

PP01.12: Col3A1: A New Immunohistological Marker for Malignant Pleural Mesothelioma
Christophe Blanquart, CRCINA, France

PP01.13: Brain-Derived Neurotrophic Factor (BDNF): A New Soluble Biomarker for Malignant Pleural Mesothelioma
Christophe Blanquart, CRCINA, France

PP01.14: Assessment of New HDAC Inhibitors for Immunotherapy of Malignant Pleural Mesothelioma
Christophe Blanquart, CRCINA, France

PP01.15: A 3D Explant Model Demonstrates the Therapeutic Efficacy of Newly Developed BH3-Mimetics
Xiao-Ming Sun, University of Leicester, United Kingdom

PP01.16: Allogeneic Antibody Therapy for Malignant Mesothelioma
Hee-Jin Jang, Baylor College of Medicine, United States

PP01.17: Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma
Viljem Kovac, Institute of Oncology Ljubljana, Slovenia

PP01.18: Targeting Cullin Ubiquitin Ligase in Malignant Pleural Mesothelioma
Michaela Kirschner, University Hospital Zürich, Switzerland

PP01.19: A Combined microRNA-Clinical Score as Prognostic Factor for Malignant Pleural Mesothelioma
Michaela Kirschner, University Hospital Zürich, Switzerland
PP01.20: Anti-Tumor Effect of Curcumin Alone or in Combination with Cisplatin-Based Chemotherapy in a Mouse Mesothelioma Model
Chengke Zhang, The Second Hospital of Shandong University, China

PP01.21: Targeting Protein Synthesis Reshapes Bioenergetics of Malignant Mesothelioma Primary Cells and Overcomes Chemo-Resistance
Stefano Grosso, University of Leicester, United Kingdom

PP01.22: Effects of Dexamethasone Co-Medication on Chemo-Immunotherapy Treatment in Murine Mesothelioma Models
Anna Nowak, University of Western Australia, Australia

PP01.23: The Identification of a CD8+ T Cell Response to a Predicted Neoantigen in a Malignant Mesothelioma Patient
Sophie Sneddon, National Centre for Asbestos Related Diseases, Australia

PP01.24: DKK1 as a Novel Therapeutic Target in Mesothelioma
Alice Guazzelli, University of Salford, United Kingdom

PP01.25: An MDM2 Inhibitor Achieves Synergistic Cytotoxicity with Oncolytic Adenoviruses on Mesothelioma with the Wild-Type p53 Gene
Masatoshi Tagawa, Chiba Cancer Center Research Institute, Japan

PP01.26: The Retinoblastoma Family Protein RBL2/p130 Induces Apoptosis in Mesothelioma Cells upon Different Antitumoral Treatments
Francesca Pentimalli, National Cancer Institute of Naples Pascale Foundation, Italy

PP01.27: Precision Cut Tissue Slices (PCTS) of Human Mesotheliomas as a Model for Testing Immuno-Modulatory Compounds Ex Vivo
Astero Klampatsa, University of Pennsylvania, United States

PP01.28: Do Mutated Mesothelioma Neo-Antigens Have the Potential to be Effective as Treatment Vaccines?
Jenette Creaney, University of Western Australia, Australia

PP01.29: Whole Genome Sequencing of Malignant Pleural Mesothelioma
Jenette Creaney, University of Western Australia, Australia

PP01.30: An Asbestos-Exposed Mesothelioma Family without Evidence for a BAP1 Predisposing Mutation
Marieke Hylebos, University of Antwerp, Belgium

PP01.31: Genetic Polymorphisms of PD-L1 May Influence Response to Platinum-Based Chemotherapy in Malignant Mesothelioma
Vita Dolzan, University of Ljubljana, Slovenia
PP01.32: Oncogenic Features of KDM4A Histone Demethylase in Mesothelioma
Moshe Lapidot, Brigham and Women's Hospital, United States

PP01.33: Upregulation of Wnt Family Proteins May Limit Efficacy of FAK Tyrosine Kinase Inhibitors in Mesothelioma
Christina Addison, Ottawa Hospital Research Institute, Canada

PP01.34: The FAK Inhibitor BI853520 Exerts Anti-Tumor Activity in Malignant Pleural Mesothelioma
Alireza Hoda, Medical University of Vienna, Austria

PP01.35: Inhibition of Autophagy Initiation Potentiates Chemosensitivity in Mesothelioma
Carlo Follo, University of California San Francisco, United States

PP01.36: Assessing the Impact of Voluntary Exercise on Tumour Growth and Treatment in Pre-Clinical Models of Mesothelioma
Scott Fisher, National Centre for Asbestos Related Diseases, Australia

PP01.37: Partial Antiviral Type I Interferon Response by Mesothelioma Cells Sensitive to the Oncolytic Activity of Measles Virus
Jean-François Fonteneau, INSERM, France

PP01.38: How Pleural Mesothelioma Nodules Remodel Their Surroundings to Vascularize and Grow: Findings from Orthotopic Mouse Models
Ildikó Kovacs, National Korányi Institute of Pulmonology, Hungary

PP01.39: Whole-Genome RNAi Screen Reveals a Potential Therapy Depending on BAP1 Status in Malignant Pleural Mesothelioma
Agata Okonska, University Hospital Zürich, Switzerland

PP01.40: Suppression of SIRT1 Sensitizes BAP1 Wild-Type Malignant Pleural Mesothelioma Cells to the EZH2 Inhibitor EPZ6438
Laura Moro, University of Piemonte Orientale, Italy

PP01.41: Inhibition of Lysine Methyltransferase EZH2 Improves Tumoricidal Activity of Macrophages towards Mesothelioma Cells
Malik Hamaidia, University of Liège, Belgium

PP01.42: CDKN2A, 22q, and BAP1 in Malignant Pleural Mesothelioma
Nhien Dao, Brigham and Women's Hospital, United States
Track: Epidemiology

PP02.01: Trends in Mesothelioma Deaths Using Four Different Data Repositories in South Africa
Michel Muteba, University of the Witwatersrand, South Africa

Anabelle Gilg Soit Ilg, Sante Publique France, France

PP02.03: Three Asbestos Ores, Three Epidemics, Many Questions
Jim teWaterNaude, Asbestos Relief Trust, South Africa

PP02.04: Predicting Mesothelioma Incidence in a Crocidolite Asbestos-Exposed Cohort: The MINKS Study Revisited
Jim teWaterNaude, Asbestos Relief Trust, South Africa

PP02.05: Prospective Registry Database of Patients with Malignant Mesothelioma in Japan
Seiki Hasegawa, Hyogo College of Medicine, Japan

PP02.06: A Case Series with Unusual Exposures
John Oudyk, Occupational Health Clinics for Ontario Workers, Canada

PP02.07: New Approaches to Investigating Malignant Mesothelioma Associated with Naturally Occurring Asbestos Exposures
Francine Baumann, University of New Caledonia, New Caledonia

PP02.08: Asbestos Consumption, Eternit and Pleural Mesothelioma in Norway and Denmark: Similar Populations, Different Stories
Oluf Dimitri Røe, Norwegian University of Science and Technology, Norway

PP02.09: Criteria and Prognostic Factors among Sarcomatoid Malignant Pleural Mesothelioma Patients: NCI Experience
Hala Aziz Shokralla, National Cancer Institute, Egypt

PP02.10: Evaluating Impact of Mesothelioma Underascertainment
Leonid Kopylev, United States Environmental Protection Agency, United States

PP02.11: Epidemiological Differences in Mesothelioma Patients with Environmental Asbestos Exposure in Rural Area
Selma Metintas, Eskisehir Osmangazi University, Turkey

PP02.12: Familial Risk of Malignant Mesothelioma
Tianhui Chen, Zhejiang Academy of Medical Sciences, China
PP02.13: Caucasian Women with Malignant Pleural Mesothelioma
Katherina Sreter, University Hospital Centre "Sestre Milosrdnice", Croatia
Track: Imaging

PP03.01: Relationship of New Staging System with Survival in Malignant Pleural Mesothelioma Patients
Guntulu Ak, Eskisehir Osmangazi University, Turkey

PP03.02: Prospective Analysis of the Diagnostic Yield of MRI after Talc Pleurodesis in Malignant Pleural Mesothelioma
Alessia Stanzi, S. Croce e Carle General Hospital, Italy

PP03.03: Geometric Considerations for Measurement of the Diaphragm: Implications for Mesothelioma Thickness Measurements
Christopher Straus, University of Chicago, United States

PP03.04: Interobserver Variability of Quantitative Assessment using MR in Malignant Pleural Mesothelioma
Ritu Gill, Beth Israel Deaconess Medical Center, United States
Track: Medical Oncology

PP04.01: Antiproliferative Effect of a Novel 13-(Di)arylalkyl Berberine in Malignant Mesothelioma Cells
Carme Plasencia, AROMICS, Spain

PP04.02: Inhibition of the HGF/C-Met for Mesothelioma with an Intra-Pleural Injection of the NK4 Gene-Expressing Adenoviral Vectors
Yuji Tada, Chiba University, Japan

PP04.03: The Presence of Immune Cells and Immune Checkpoints as Therapeutic Targets in Mesothelioma Effusions
Elly Marcq, University of Antwerp, Belgium

PP04.04: Maintenance Gemcitabine in Malignant Mesothelioma: A Randomized Phase II Study, NVALT19. Trial in Progress
Cornedine Jannette De Gooijer, The Netherlands Cancer Institute, Netherlands

PP04.05: Phase II LUME-Meso Study of First-Line Nintedanib + Chemo in Malignant Pleural Mesothelioma: Additional Efficacy Analyses
Sanjay Popat, Royal Marsden Hospital NHS Foundation Trust, United Kingdom

PP04.06: New Prognostic Markers in Malignant Pleural Mesothelioma
Sara Ricciardi, University of Pisa, Italy

PP04.07: Real-World Experience with Checkpoint Inhibition and PD-L1 Expression in Patients with Malignant Pleural Mesotheliomas
Wei-Chu Lai, Memorial Sloan Kettering Cancer Center, United States

PP04.08: Malignant Pleural Mesothelioma: Brain Metastases and Immunotherapy
Ina Nordman, Calvary Mater Newcastle, Australia

PP04.09: Phase I/II Clinical Trial to Assess Safety and Efficacy of HVJ-E in Chemotherapy-Resistant Pleural Mesothelioma Patients
Chunman Lee, Osaka University, Japan

PP04.10: Effects of Tumor Burden Reduction on Survival in Epithelioid Pleural Mesothelioma
Aaron Mansfield, Mayo Clinic, United States

PP04.11: Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma: Phase II Biomarker Data from the LUME-Meso Study
Federica Grosso, SS Antonio e Biagio Hospital, Italy
**PP04.12: Clinical Characteristics of Malignant Pleural Mesothelioma in the Early Stage**
Yuichi Koda, Hyogo College of Medicine, Japan

**PP04.13: Outcomes of Mesothelioma Patients on CCTG IND.226: A Phase Ib of Durvalumab (D) +/- Tremelimunab (T) +/- Platinum Doublets**
Scott Laurie, The Ottawa Hospital, Canada

**PP04.14: Outcomes of Nonepithelioid Pleural Mesothelioma in Recent Trials**
Abdullah Nasser, The Ottawa Hospital, Canada

**PP04.15: Tracking the Chemotherapy Resistance of Malignant Pleural Mesothelioma**
Kathrin Oehl, University Hospital Zürich, Switzerland

**PP04.16: MesoBreath 4: Designing the External Validation of a Breath Test for the Early Detection of Malignant Pleural Mesothelioma**
Kevin Lamote, University of Antwerp, Belgium

**PP04.17: Time to Treatment Initiation and Outcomes in Malignant Pleural Mesothelioma: An NCDB Review**
Christopher Wee, Cleveland Clinic Foundation, United States

**PP04.18: MVA-5T4 (TroVax) Vaccine and Combination Chemotherapy in MPM: Results of a Phase II Trial and Immuno-Profiling**
Zsuzsanna Tabi, Cardiff University, United Kingdom

**PP04.19: The Factors of Better Prognosis for Mesothelioma**
Takumi Kishimoto, Okayama Rosai Hospital, Japan

**PP04.20: Malignant Pleural Mesothelioma (MPM) in Egypt: Is It Different?**
Fatma Aou El-Kasem, Medical Oncology National Cancer Institute, Egypt

**PP04.21: Zoledronic Acid in the Management of Mesothelioma: A Feasibility Trial (Zol-A Trial)**
Duneesha De Fonseka, University of Bristol, United Kingdom

**PP04.22: CRP/Albumin Ratio as a Prognostic Marker in Patients with Malignant Pleural Mesothelioma Receiving Active Treatment**
Duneesha De Fonseka, University of Bristol, United Kingdom
Track: Nursing

PP05.01: Our Research Priorities in Mesothelioma: Replicating the James Lind Alliance PSP Project in a Small Group Setting
Simon Bolton, Harrogate & District NHS Foundation Trust, United Kingdom
Track: Pathology

PP06.01: Glut1 in the Role of Peritoneal Malignant Mesothelioma Diagnosis and Differential Diagnosis
Gao Zhibin, Yuyao People's Hospital, China

PP06.02: Impact of Calretinin Immunohistochemistry and the iMig Guidelines in the Malignant Mesothelioma Diagnosis
Vasiliki Panou, Aalborg University Hospital, Denmark
Track: Radiation Oncology

PP07.01: The Abscopal Effect in Malignant Mesothelioma: Report on a Case Series
Kenneth O’Byrne, Queensland University of Technology, Australia
Track: Surgery

PP08.01: Is Toxicity Increased by Adding Intraoperative Chemotherapy to Preoperative Induction Chemotherapy for Mesothelioma Patients?
Olivia Lauk, University Hospital Zürich, Switzerland

PP08.02: Adding Bevacizumab to Standard Induction Chemotherapy for Pleural Mesothelioma Raises the Risk for Postoperative Bleeding?
Olivia Lauk, University Hospital Zürich, Switzerland

PP08.03: Is Extended Pleurectomy/Decortication Superior to Pleurectomy/Decortication for Malignant Pleural Mesothelioma Patients?
Olivia Lauk, University Hospital Zürich, Switzerland

PP08.04: Does Neo-Adjuvant Chemotherapy Affect the Outcomes of Extended Pleurectomy Decortication?
Alan Dawson, Glenfield Hospital, United Kingdom

PP08.05: Searching for MARS-2: A United Kingdom Cancer Network’s Specialist Mesothelioma MDT Screening Experience
Shereen Ajab, Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom

PP08.06: Independent Lung Ventilation Technique for the eP/D Operation for Malignant Pleural Mesothelioma
Takao Morohoshi, Yokosuka Kyosai Hospital, Japan

PP08.07: Outcomes of Multidisciplinary Treatment including Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma
In Kyu Park, Seoul National University Hospital, South Korea
Track: Symptom Control / Palliative Care

PP09.01: Malignant Pleural Mesothelioma among Young People in Central Region of Uganda (Developing Nations Award Winner)
Nehemiya Igulu, Uganda Cancer Institute/Makerere University, Uganda
Track: Patient Advocacy

PP10.01: Zoledronic Acid in the Management of Mesothelioma: A Feasibility Trial (Zol-A Trial) Qualitative Sub-Study
Duneesha De Fonseka, University of Bristol, United Kingdom

PP10.02: Further Update: Impact of BAP1 Mutation on Mesothelioma Risk and Implications for Mesothelioma Litigation
Steven Kazan, Kazan McClain Satterley & Greenwood, United States